Tango Therapeutics, Inc. TNGX
Tango Therapeutics, Inc. (Nasdaq: TNGX) is an oncology drug developer. Its lead program, vopimetostat (TNG462), is in Phase 2 for MTAP-deleted cancers incl. pancreatic (PRMT5 inhibitor). Its next catalyst on record is vopimetostat: ESMO combination data (October 2026).
Upcoming catalysts
- October 2026vopimetostat — ESMO combination data
ESMO 2026-10-23 to 27
Next further out: vopimetostat — Erasca combination Phase 1/2 start (H2 2026). 9 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| vopimetostat | MTAP-del PDAC and others | small molecule | Phase 2 |
| TNG456 | Glioblastoma | small molecule | Phase 1 |
| TNG260 | Solid tumors | small molecule | Phase 1 |
| TNG961 | Undisclosed | small molecule | Pre-clinical |
Recent results and decisions
- Oct 23, 2026positive Vopimetostat plus daraxonrasib demonstrated 82% ORR, median PFS not reached, and 88% 9-month PFS rate in 22 patients with 2L/3L MTAP-deleted PDAC.
82% objective response rate (ORR), median PFS not yet reached, and a 9-month PFS rate of 88%, in 22 patients with 2L/3L MTAP-deleted/RAS-mutant PDAC who were efficacy-evaluable.
Filing - Oct 22, 2026n/a The Company approved a strategic reprioritization to focus on PRMT5-targeted therapies and reduce workforce by approximately 14%.
On October 22, 2026, the Board of Directors of the Company approved a strategic reprioritization of the Company's research and development activities to focus its efforts on the advancement of PRMT5-targeted therapies
Filing - Oct 22, 2026n/a Tango approved strategic reprioritization to focus on PRMT5-targeted therapies and reduce workforce by approximately 14%.
the Board of Directors of the Company approved a strategic reprioritization of the Company's research and development activities to focus its efforts on the advancement of PRMT5-targeted therapies
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
- Faeth Therapeutics, Inc. FTH
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.